Preview

Medical Immunology (Russia)

Advanced search

CYTOKINE REGULATION IN THE COURSE OF MULTIPLE MYELOMA PROGRESSION

https://doi.org/10.15789/1563-0625-2015-3-261-268

Abstract

Cytokines are wide-range modifiers of biological reactions. Cytokine regulation provides proliferation, differentiation, cell function, cell-cell and inter-systemic interaction, direction and nature of immune response to invasion of infectious and non-infectious pathogens. There are several distinct groups of cytokines: pro-inflammatory, anti-inflammatory factors, regulators of cellular and humoral immunity etc. A distinct role of cytokines is not excluded for infectious complications accompanying multiple myeloma (MM). Cytokine regulatory effects on immune defense in the organism as a whole, and a balance between proand anti-inflammatory cytokines in blood of MM patients depend on the stage of multiple myeloma progression and possibility of infectious complications. Therefore, the aim of our study was to evaluate proand anti-inflammatory cytokines and cytokine regulation in patients with MM G-immunochemical option. Our study involved 101 patients with MM (IgG-variant), their age ranging between 40 and 76 years. The diagnosis was verified by clinical and laboratory examinations. The G-variant of MM was verified by immunofixation and electrophoresis. The definite diagnosis and disease staging was confirmed by a combination of diagnostic criteria. Heparinized blood samples were taken from the cubital vein in the morning (8 to 9 hours), in fasting state upon admission, prior to the starting a pathogenetic therapy. Dynamic monitoring of patients was carried out over the period of their staying in hospital. All patients were staged according to Durie and Salmon (1975) (stages II, III). At each stage, we discerned two sub-groups: A, without renal disease, B, with renal impairment. The control group consisted of 125 healthy volunteers matched for age and sex with the main group. IL-2, IL-4, IL-8, TNFα, and IFNγ levels in sera of the patients and healthy individuals were determined by enzyme immunoassay kits (JSC “Vector-Best”,Novosibirsk). In the myeloma patients, we have revealed an imbalance between pro-inflammatory (IL-2, IL-8, TNFα, IFNγ), and antiinflammatory cytokines (IL-4), with a predominance of pro-inflammatory factors. This finding does not exclude their potential pathogenetic role in growth and stimulation of tumor progression, and occurrence of infectious complications at any stage of the disease. The disturbances in cytokine regulation in MM patients may manifest as a deviation of cellular immune response by Th-1 way. As seen from our data, TNFα, IL-2 and IL-4 are the most significant cytokines for MM progression.

About the Authors

O. V. Smirnova
Research Institute for Medical Problems of the North, Krasnoyarsk
Russian Federation
PhD, MD (Medicine), Head, Laboratory of Clinical Pathophysiology


V. T. Manchuk
Research Institute for Medical Problems of the North, Krasnoyarsk
Russian Federation
PhD, MD (Medicine), Corresponding Member, Russian Academy of Sciences, Scientific Manage


T. V. Polivanova
Research Institute for Medical Problems of the North, Krasnoyarsk
Russian Federation
Main Research Associate


Yu. N. Agilova
Research Institute for Medical Problems of the North, Krasnoyarsk
Russian Federation
Junior Research Associate, Laboratory of Clinical Pathophysiology


References

1. Романенко Н.А., Бессмельцев С.С., Розанова О.Е., Карпова Н.С., Абдулкадыров К.М. Влияние уровня ФНО-α на эффективность коррекции анемии у больных лимфопролиферативными заболеваниями // Онкогематология, 2010. № 3. С. 22-28. [Romanenko N.A., Bessmeltsev S.S., Rozanov O.E., Karpov N.S., Abdulkadyrov K.M. Influence the level of TNF-α on the effectiveness of the correction of anemia in patients with lymphoproliferative diseases. Onkogematologiya = Oncohematology, 2010, no. 3, pp. 22-28. (In Russ.)]

2. Кадагидзе З.Р. Цитокины // Практонкол, 2003. Т. 4, № 3. С. 2-9. [Kadagidze Z.R. Cytokines. Praktonkol = Praktonkol, 2003, Vol. 4, no. 3, pp. 2-9. (In Russ.)]

3. Манчук В.Т., Смирнова О.В. Использование методов нейросетевого моделирования и дискриминантного анализа для оценки состояния иммунного статуса у больных острым нелимфобластным лейкозом // Якутский медицинский журнал, 2010. № 2. С. 77-79. [Manchuk V.T., Smirnova O.V. The use of neural network modeling and discriminant analysis to assess the immune status in patients with acute leukemia nelimfoblastnyh. Yakutskiy meditsinskiy zhurnal = Yakut Medical Journal, 2010, no. 2, pp. 77-79. (In Russ.)]

4. Манчук В.Т., Смирнова О.В. Особенности прогнозирования возникновения инфекционных осложнений после проведения химиотерапии у больных острыми лейкозами // Медицинская иммунология, 2012. Т. 14, № 4-5. С. 403-408. [Manchuk V.T., Smirnova O.V. Features prediction of occurrence of infectious complications after chemotherapy in patients with acute leukemia. Meditsinskaya immunologiya = Medical Immunology (Russia), 2012, Vol. 14, no. 4-5, pp. 403-408. (In Russ.)]

5. Матвеева Л.В., Мосина Л.М., Митина Е.А. Интерлейкиновый профиль крови в сопоставлении с выраженностью воспалительного, атрофического и ульцерозного процессов в слизистой оболочке желудка // Фундаментальные исследования, 2013. № 7-1. С. 133-137. [Matveeva L.V., Mosin L.M., Mitin E.A. Interleukin blood profile in relation to the severity of inflammation, atrophic and ulcerous processes in the gastric mucosa. Fundamental`nye issledovaniya = Basic Research, 2013, no. 7-1, pp. 133-137. (In Russ.)]

6. Особенности диагностики и лечения пневмонии у больных множественной миеломой / В.В. Войцеховский, Ю.С. Ландышев, А.А. Григоренко, Т.А. Савинова, С.Ю. Ландышев, С.А. Горячева, В.П. Мишук // Бюллетень физиологии и патологии дыхания, 2013. № 50. С. 23-29. [Diagnosis and treatment of pneumonia in patients with multiple myeloma / V.V. Voytsekhovskiy, Yu.S. Landyshev, A.A. Grigorenko, T.A. Savinova, S.Yu. Landyshev, S.A. Goryachev, V.P. Mishuk. Byulleten` fiziologii i patologii dykhaniya = Bulletin of the Physiology and Pathology of Breathing, 2013, no. 50, pp. 23-29. (In Russ.)]

7. Росси Ж.Ф. Интерлейкин – 6 как терапевтическая мишень при иммунопатологии и онкологических заболеваниях // Иммунология гемопоэза, 2012. Т. 10, № 2. С. 8-34. [Rossi J.F. Interleukin – 6 as a therapeutic target in cancer and immunopathology. Immunologiya gemopoeza = Immunology Hematopoiesis, 2012, Vol. 10, no. 2, pp. 8-34. (In Russ.)]

8. Савченко А.А., Смирнова О.В., Манчук В.Т., Москов В.И. Способ прогнозирования инфекционных осложнений после химиотерапии у больных острыми лейкозами // патент на изобретение RUS 2315305 08.11.2005 [Savchenko A.A., Smirnova O.V., Manchuk V.T., Moscov V.I. A method of predicting infectious complications after chemotherapy in patients with acute leukemia, patent 2315305 RUS 08.11.2005

9. Смирнова О.В. Хронический миелолейкоз – клинические и иммунологические особенности у взрослых больных // Бюллетень Восточно-Сибирского научного центра СО РАМН, 2012. № 3-2. С. 185-189. [Smirnova O.V. Chronic myelogenous leukemia – clinical and immunological features in adults. Byulleten` VostochnoSibirskogo nauchnogo tsentra SO RAMN = Bulletin of the East Siberian Scientific Center of the Academy of Medical Sciences, 2012, no. 3-2, pp. 185-189. (In Russ.)]

10. Смирнова О.В., Манчук В.Т., Савченко А.А. Особенности клинических проявлений и характеристика иммунопатогенеза больных хроническим миелолейкозом // Сибирский онкологический журнал, 2007. № 3. С. 16-22. [Smirnova O.V., Manchuk V.T., Savchenko A.A. Clinical manifestations and characteristics of the immunopathogenesis of chronic myeloid leukemia. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology, 2007, no. 3, pp. 16-22. (In Russ.)]

11. Смирнова О.В., Манчук В.Т., Савченко А.А. Состояние иммунного статуса и активность ферментов в лимфоцитах крови у больных на разных стадиях острого лимфобластного лейкоза // Медицинская иммунология, 2008. Т. 10, № 6. С. 543-550. [Smirnova O.V., Manchuk V.T., Savchenko A.A. Immune status and activity of enzymes in blood lymphocytes in patients at different stages of acute lymphoblastic leukemia. Meditsinskaya immunologiya = Medical Immunology (Russia), 2008, Vol. 10, no. 6, pp. 543-550. (In Russ.)]

12. Смирнова О.В., Савченко А.А., Манчук В.Т. Клинико-иммунологические проявления и нарушения метаболизма внутриклеточных ферментов лимфоцитов у больных хроническим лимфолейкозом // Си бирский онкологический журнал, 2007. № 2. С. 15-21. [Smirnova O.V., Savchenko A.A., Manchuk V.T. Clinical and immunological manifestations and metabolic disturbances of intracellular enzymes of lymphocytes in patients with chronic lymphocytic leukemia. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology, 2007, no. 2, pp. 15-21. (In Russ.)]

13. Cytokine profiles of multiple myeloma and Waldenström macroglobulinemia / L. Sedlaříková, K. Sadílková, L. Kubiczková, R. Hájek, S. Sevčíková. Klin Onkol., 2014, Vol. 27, no. 1, pp. 18-23.

14. Smirnova O.V., Manchouk V.T., Savchenko A.A. Immune status & enzymes activity in blood lymphocytes in adult patients at different stages of acute lymphoblastic leukaemia. Indian Journal of Medical Research, 2011, Vol. 133, no. 3, pp. 280-286.

15. Zheng M.M., Zhang Z., Bemis K., Belch A.R., Pilarski L.M., Shively J.E., Kirshner J. The systemic cytokine environment is permanently altered in multiple myeloma. PLoS One, 2013, Vol. 8, no. 3, pp. 12-16.


Review

For citations:


Smirnova O.V., Manchuk V.T., Polivanova T.V., Agilova Yu.N. CYTOKINE REGULATION IN THE COURSE OF MULTIPLE MYELOMA PROGRESSION. Medical Immunology (Russia). 2015;17(3):261-268. (In Russ.) https://doi.org/10.15789/1563-0625-2015-3-261-268

Views: 1955


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1563-0625 (Print)
ISSN 2313-741X (Online)